Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system.

ABSTRACT:

Introduction

The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients' symptomatic and functional status.

Purpose

This study aimed to evaluate the cost-effectiveness of the MBC regimen (Mavacamten plus a β-blocker or a calcium-channel blocker) versus the PBC regimen (placebo plus a β-blocker or a calcium-channel blocker) for treating Obstructive Hypertrophic Cardiomyopathy from the perspective of the Chinese Healthcare System.

Methods

A Markov model was constructed using data from the EXPLORER-HCM clinical trial. Cost and utility inputs were sourced from public databases and published literature. Tot

SUBMITTER: Qian J 

PROVIDER: S-EPMC12927379 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature